Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Expenses (2016 - 2025)

Altimmune (ALT) has disclosed Accumulated Expenses for 16 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 4.19% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 4.19% increase, with the full-year FY2024 number at $3.1 million, down 7.12% from a year prior.
  • Accumulated Expenses was $2.4 million for Q3 2025 at Altimmune, down from $5.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $19.1 million in Q3 2021 to a low of $1.0 million in Q1 2025.
  • A 5-year average of $6.4 million and a median of $5.4 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 6958.5% in 2021, then tumbled 88.12% in 2022.
  • Altimmune's Accumulated Expenses stood at $2.3 million in 2021, then skyrocketed by 429.62% to $12.2 million in 2022, then tumbled by 72.94% to $3.3 million in 2023, then fell by 7.12% to $3.1 million in 2024, then dropped by 21.7% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Accumulated Expenses are $2.4 million (Q3 2025), $5.4 million (Q2 2025), and $1.0 million (Q1 2025).